Low-grade brain tumors known as IDH-mutant gliomas CNS WHO grade 2 are life-threatening in spite of their slow growth.
Researchers at Mount Sinai launch a new AI platform to match more cancer patients with clinical trials, aiming to expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback